- Home
- IMUX vs JMM Comparison
IMUX vs JMM Comparison
Compare IMUX & JMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- JMM
- Stock Information
- Founded
- IMUX 2016
- JMM 1988
- Country
- IMUX United States
- JMM United States
- Employees
- IMUX N/A
- JMM N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- JMM Trusts Except Educational Religious and Charitable
- Sector
- IMUX Health Care
- JMM Finance
- Exchange
- IMUX Nasdaq
- JMM Nasdaq
- Market Cap
- IMUX 67.8M
- JMM 58.6M
- IPO Year
- IMUX N/A
- JMM N/A
- Fundamental
- Price
- IMUX $0.81
- JMM $6.23
- Analyst Decision
- IMUX Strong Buy
- JMM
- Analyst Count
- IMUX 6
- JMM 0
- Target Price
- IMUX $11.60
- JMM N/A
- AVG Volume (30 Days)
- IMUX 1.8M
- JMM 16.1K
- Earning Date
- IMUX 08-07-2025
- JMM 01-01-0001
- Dividend Yield
- IMUX N/A
- JMM 5.44%
- EPS Growth
- IMUX N/A
- JMM N/A
- EPS
- IMUX N/A
- JMM N/A
- Revenue
- IMUX N/A
- JMM N/A
- Revenue This Year
- IMUX N/A
- JMM N/A
- Revenue Next Year
- IMUX N/A
- JMM N/A
- P/E Ratio
- IMUX N/A
- JMM N/A
- Revenue Growth
- IMUX N/A
- JMM N/A
- 52 Week Low
- IMUX $0.56
- JMM $5.29
- 52 Week High
- IMUX $2.11
- JMM $6.10
- Technical
- Relative Strength Index (RSI)
- IMUX 54.61
- JMM 50.20
- Support Level
- IMUX $0.68
- JMM $6.22
- Resistance Level
- IMUX $0.83
- JMM $6.41
- Average True Range (ATR)
- IMUX 0.05
- JMM 0.10
- MACD
- IMUX 0.02
- JMM -0.00
- Stochastic Oscillator
- IMUX 89.29
- JMM 42.55
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.